BIOMARIN PHARMACEUTICAL INC — Form 8-K
Filed September 14, 2026 · analyzed by the 8-K Agent
8-K
— Neutral
significance 8/100
What the filing says
BioMarin filed an 8-K on 2026-09-14 disclosing Item 5.02 (departure of directors/officers, election of directors, appointment of officers, and compensatory arrangements). The filing document does not contain the specific names, titles, dollar amounts, share counts, or dates of the actual changes—only the structural metadata indicating the report covers events as of 2026-09-10. The substantive content of Item 5.02 is not provided in this extracted header/index view.
Why this rating
Officer/director events are routine disclosures; specifics unavailable in this filing metadata extract. Cannot assess materiality without actual compensation or role details.
Extracted items
See more from September 14, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.